Literature DB >> 1347987

Sulphasalazine induced hepatitis in juvenile rheumatoid arthritis.

D Caspi1, D Fuchs, M Yaron.   

Abstract

Two 19 year old patients with juvenile chronic arthritis developed liver toxicity during treatment with sulphasalazine. A significant increase in the levels of liver enzymes in serum samples was noticed in relation to the initiation of treatment in one patient and to the increase in dose in the second. The enzymes returned to normal levels 14 days after the drug had been stopped. A rechallenge in one of the patients caused re-exacerbation. This is the first report of liver toxicity induced by sulphasalazine in juvenile chronic arthritis. As spontaneous liver involvement in juvenile chronic arthritis is not rare, the possibility of drug induced hepatitis should be recognised in these patients.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1347987      PMCID: PMC1005674          DOI: 10.1136/ard.51.2.275

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  12 in total

Review 1.  Advanced drug therapy for juvenile rheumatoid arthritis.

Authors:  A M Rosenberg
Journal:  J Pediatr       Date:  1989-02       Impact factor: 4.406

2.  Hepatic involvement in juvenile rheumatoid arthritis.

Authors:  J Schaller; B Beckwith; R J Wedgwood
Journal:  J Pediatr       Date:  1970-08       Impact factor: 4.406

3.  Salazopyrin-induced eosinophilic pneumonia.

Authors:  S Berliner; A Neeman; Y Shoenfeld; M Eldar; I Rousso; U Kadish; J Pinkhas
Journal:  Respiration       Date:  1980       Impact factor: 3.580

Review 4.  Sulfasalazine in the rheumatic disease.

Authors:  R S Pinals
Journal:  Semin Arthritis Rheum       Date:  1988-05       Impact factor: 5.532

5.  [The treatment of rheumatoid polyarthritis using salazosulfapyridine (Salazopyrine). A 6-month open study of 34 patients].

Authors:  R Ghozlan; M Dupuis; A Schwak; P Jorro; C Lecarpentier; C Guillon
Journal:  Rev Rhum Mal Osteoartic       Date:  1988-02

Review 6.  Sulfasalazine-induced hepatotoxicity in children with inflammatory bowel disease.

Authors:  D L Boyer; B U Li; J N Fyda; R A Friedman
Journal:  J Pediatr Gastroenterol Nutr       Date:  1989-05       Impact factor: 2.839

7.  Sulphasalazine (Salazopyrin) in the treatment of enterogenic reactive synovitis and ankylosing spondylitis with peripheral arthritis.

Authors:  H Mielants; E M Veys; R Joos
Journal:  Clin Rheumatol       Date:  1986-01       Impact factor: 2.980

8.  Chronic salicylate administration in juvenile rheumatoid arthritis: aspirin "hepatitis" and its clinical significance.

Authors:  J G Schaller
Journal:  Pediatrics       Date:  1978-11       Impact factor: 7.124

9.  [Therapy of juvenile chronic arthritis with sulfasalazine].

Authors:  H J Suschke
Journal:  Z Rheumatol       Date:  1987 Mar-Apr       Impact factor: 1.372

10.  Sulphasalazine in the treatment of juvenile rheumatoid arthritis: a preliminary open trial.

Authors:  H Ozdogan; M Turunç; B Deringöl; S Yurdakul; H Yazici
Journal:  J Rheumatol       Date:  1986-02       Impact factor: 4.666

View more
  7 in total

1.  Sulphasalazine induced hepatitis in adult Still's disease.

Authors:  J Crowley; R D Situnayake
Journal:  Ann Rheum Dis       Date:  1992-11       Impact factor: 19.103

2.  The three week sulphasalazine syndrome.

Authors:  H Brooks; H G Taylor; F E Nichol
Journal:  Clin Rheumatol       Date:  1992-12       Impact factor: 2.980

3.  Still disease and the liver-an underappreciated association.

Authors:  Kieron B L Lim; Thomas D Schiano
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-12

Review 4.  Juvenile rheumatoid arthritis: therapeutic perspectives.

Authors:  Ian C Chikanza
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

5.  Sulphasalazine in the treatment of pauciarticular-onset juvenile chronic arthritis.

Authors:  A Gedalia; J Barash; J Press; D Buskila
Journal:  Clin Rheumatol       Date:  1993-12       Impact factor: 2.980

Review 6.  Gastrointestinal and hepatic manifestations of rheumatoid arthritis.

Authors:  Ellen C Ebert; Klaus D Hagspiel
Journal:  Dig Dis Sci       Date:  2011-01-04       Impact factor: 3.487

7.  Successfully treated sulphasalazine-induced fulminant hepatic failure, thrombocytopenia and erythroid hypoplasia with intravenous immunoglobulin.

Authors:  J L Huang; I J Hung; L C Chen; W Y Lee; C Hsueh; K H Hsieh
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 3.650

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.